Asacol Buyers Say Product-Hopping Suit Requires Trial
Law360 (June 18, 2019, 5:54 PM EDT) -- Buyers of Allergan's ulcerative colitis drugs have told a Massachusetts federal court that they were coerced into paying for higher-priced medication when the company blocked a generic drug from the market, which they say is enough to push their antitrust case to trial.
The end-payors urged the court to deny the drugmaker's request for summary judgment, claiming they were definitely injured by Allergan PLC subsidiary Warner Chilcott Ltd.’s so-called product-hopping. In a brief unsealed Monday, the payors said they’ve proven an injury because if Allergan hadn’t taken a product with expiring patents off the market and replaced it with a patent-protected version,...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!